News | June 16, 2022
Glenmark becomes the first company to launch Indacaterol + Mometasone FDC for asthma in India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Bayer now present in four of the largest biotechnology hubs in the United States
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Auld is a seasoned Financial Executive with over 30 years of relevant experience
The product will be launched by NATCO's commercial partner Viatris.
Subscribe To Our Newsletter & Stay Updated
